Health System News

EUA Antibody Therapy

November 30, 2020, Monday

In the last three weeks, two antibody therapies for non-hospitalized patients age 12 and older with mild to moderate symptoms of COVID-19 have received emergency use authorization (EUA). Bamlanivimab and casirivimab/imdevimab are single and combination monoclonal antibody therapies directed toward the spike protein of SARS-CoV-2. Both of these agents received an EUA based on limited clinical trial data. These data show potential decrease in progression to severe disease, but only when administered early in the course of the disease. Neither agent is considered standard of care.

We have a very limited allocation of these agents through the U.S. Department of Health and Human Services and New York State. Consequently, there is a process for screening patients who may potentially derive benefit from receipt of either of these agents. Please note the following is required for referral:

- A laboratory-confirmed diagnostic test for COVID-19 (e.g., a PCR or antigen test)
- Symptoms with symptom onset within five days
- Risk factors for progressing to severe disease
- Not requiring oxygen therapy for COVID-19

If you feel that you have a patient who fits the criteria for receipt of one of these agents, please email Covidtherapeuticreferrals@mountsinai.org or call (212) 824-8390. Please include the name and contact information of the patient/caregiver as well as your name and contact information. If the patient has a Mount Sinai medical record number, please include that in the message. An Infectious Diseases provider will follow up with a telehealth consultation to determine next steps in patients that meet the screening criteria.

We are currently able to infuse these therapies in the GP2 Oncology Care Unit at The Mount Sinai Hospital and are preparing a second Health System location that can perform therapeutic infusion services for patients requiring isolation. Updates will be provided over the coming weeks as more experience is gained and additional antibody-based COVID-19 clinical trials are initiated in the Health System.

Judith A. Aberg, MD
Chief of the Division of Infectious Diseases
Mount Sinai Health System

Gopi Patel, MD, MS
Director, Antimicrobial Stewardship Program
Mount Sinai Health System

Susan Mashni, PharmD, BCPS
Vice President
Chief Pharmacy Officer
Mount Sinai Health System